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ABSTRACT 47 
Objectives. Brachial artery flow-mediated dilation is a popular technique to examine 48 
endothelial function in humans. Identifying subject- and methodological factors related to 49 
variation in flow-mediated dilation is important to improve measurement accuracy and 50 
applicability. 51 
Methods. Subject- and methodology-related parameters were collected in 672 subjects from 8 52 
affiliated centres world-wide who underwent repeated measures of flow-mediated dilation. 53 
All centres adopted contemporary expert-consensus guidelines for flow-mediated dilation 54 
assessment. After calculating the coefficient of variation (%) of the flow-mediated dilation for 55 
each individual, we constructed quartiles (n=168 per quartile). Based on 2 regression models 56 
(1.Subject-related factors, 2.Methodology-related factors), statistically significant components 57 
of these two models were added to a final regression model (calculated as β-coefficient and 58 
R2). This allowed us to identify factors that independently contributed to the variation in flow-59 
mediated dilation%.  60 
Results. Median coefficient of variation was 17.5%, with healthy volunteers demonstrating a 61 
coefficient of variation of 9.3%. Regression models revealed age (β=0.248, P<0.001), 62 
hypertension (β=0.104, P<0.001), dyslipidemia (β=0.331,P<0.001), time between 63 
measurements (β=0.318, P<0.001), lab experience (β=-0.133, P<0.001) and baseline flow-64 
mediated dilation% (β=0.082, P<0.05) as contributors to the coefficient of variation. After 65 
including all significant factors in the final model, we found that time between measurements, 66 
hypertension, baseline flow-mediated dilation%, and lab experience with flow-mediated 67 
dilation independently predicted brachial artery variability (total R2=0.202).  68 
Conclusions. Whilst flow-mediated dilation% showed good reproducibility, larger variation 69 
was observed in conditions with longer time between measurements, hypertension, less 70 
experience and lower baseline flow-mediated dilation%. Accounting for these factors may 71 
improve flow-mediated dilation% variability. 72 
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INTRODUCTION 77 
Cardiovascular disease remains the world’s leading cause of morbidity and mortality. 78 
Previous studies have provided convincing evidence that endothelial dysfunction is an early 79 
manifestation of cardiovascular disease [1, 2], contributing to development and/or 80 
acceleration of the atherosclerotic process. Based on the detrimental role of endothelial 81 
dysfunction in this common disease process, studies have attempted to develop and validate 82 
(non-invasive) methods and biomarkers to assess endothelial function in humans. The 83 
conceptual idea is that identification of endothelial dysfunction, in symptomatic as well as 84 
asymptomatic subjects, is related to increased risk for future development of cardiovascular 85 
events [3, 4]. 86 
 87 
A frequently-used, non-invasive technique to examine endothelial function in humans in vivo 88 
is flow-mediated dilation (FMD) [5]. This measurement adopts high resolution 89 
ultrasonography to measure the conduit artery diameter dilatation in response to marked 90 
elevation in blood flow (and therefore shear stress) after a 5-minute period of distal limb 91 
ischemia [6]. Studies have provided evidence that the FMD-response is endothelium-92 
dependent [7] and largely mediated by nitric oxide [8], an important and potent vasodilator 93 
and anti-atherogenic molecule. The measurement of endothelial function using FMD has 94 
become popular in clinically-orientated studies, likely because of its non-invasive nature, 95 
ability to predict cardiovascular events [4, 9-11] and correlation to coronary artery endothelial 96 
function [2, 12].  97 
 98 
Despite its valid conceptual basis, a number of factors influence the variability of FMD [13, 99 
14]. Previous studies found that FMD is influenced by lifestyle factors (e.g. smoking, physical 100 
activity), methodology (e.g. cuff placement, duration of ischemia), intake of food and 101 
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beverages, hormonal changes, and method of analysis [8, 11]. Although many of these factors 102 
are currently being controlled for through adopting expert-consensus guidelines [11, 15], 103 
variation in FMD remains. These sources of variation may be subject-and/or methodology-104 
dependent, but this has not yet been systematically studied. Identification of such factors will 105 
contribute to the control of measurement error, which will help to appropriately power studies 106 
and aid in the construction of rigorous and standardized guidelines [11, 16]. 107 
 108 
The purpose of this study was to identify subject- and methodology-related factors that 109 
contribute to FMD variation in humans.  To this end, we combined data from previous studies 110 
(from 8 research centres) that performed repeated measurements within-subjects of brachial 111 
artery FMD in a total of 672 individuals. All included studies were performed according to 112 
expert-consensus guidelines [11]. Subsequently, we assessed subject- and methodology-113 
related factors that contributed to brachial artery FMD variability.   114 
 115 
 116 
METHODS 117 
Study population  118 
The International Working Group on Flow-Mediated Dilation (IWG-FMD) originates from 119 
eight different research groups in four different countries. All groups provided written consent 120 
to contribute their data. We compiled subject-level data from all participating research centres 121 
(see supplementary list), including a total of 19 different studies. All affiliated researchers 122 
provided details on methodology of included studies in a specifically designed questionnaire. 123 
These details were cross-checked with earlier published and/or unpublished data. All centres 124 
received an outline of the datasheet, to enhance sufficient and complete data collection. A 125 
total of 84 parameters were explored. Data from a total of 672 individuals with measurement 126 
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of the brachial artery FMD, assessed on at least two separate occasions, obtained by B-mode 127 
ultrasound systems were available for data analyses. When studies included more than one 128 
repeated measurement, only the first and second measurement were included prior to 129 
statistical analyses. All subsequent repeated measurements were rejected, to prevent distortion 130 
included parameters.  131 
 132 
Brachial artery flow mediated dilation measurements: methodological considerations 133 
We included data from participants whose FMD data were collected on 2 separate occasions 134 
without an intervention between both measurements. These measurements were limited to the 135 
brachial artery (measurements of e.g. the radial-, femoral or popliteal arteries were excluded), 136 
in either the right or left arm (consistent for both measurements). To examine brachial artery 137 
FMD, participants extend the scanned arm following a short (10-15 minutes) resting period in 138 
the supine position. A rapid inflation and deflation pneumatic cuff was positioned on the 139 
forearm of the imaged arm distal to the olecranon process to provide a stimulus of forearm 140 
ischemia [11, 15]. With an ultrasound system, B-mode images of the brachial artery in the 141 
distal third of the upper arm (above the antecubital fossa in the longitudinal plane) were made. 142 
When an optimal image was obtained, the ultrasound probe was held stable (manually or by 143 
using a clamp) and ultrasound parameters were set to optimise the longitudinal B-mode 144 
image. At least one minute of baseline diameter was recorded, after which the pneumatic cuff 145 
was inflated to at least 50 mmHg above systolic pressure to occlude arterial inflow for a 146 
standardised length of time (i.e. standardised time of 5 minutes of occlusion). Subsequent cuff 147 
deflation induced a brief high-flow (hyperaemic) state that increased wall-shear stress at the 148 
brachial artery, causing it to dilate. To assess flow velocity, a mid-artery pulsed Doppler 149 
signal was obtained during the protocol [11, 15]. Whilst all study centres used slightly 150 
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different protocols to collect the repeated FMD measurements, all followed the above 151 
described expert-consensus guidelines. 152 
 153 
Different types of ultrasound systems were used across the different centres, including; 154 
TerasonT3000 (Terason, Aloka, United Kingdom; 10-MHz multifrequency linear array 155 
transducer, n=136), Sonos 5500 (Hewlett-Packard, 7.5-MHz linear array transducer, n=20), 156 
ESAOTEMyLab25 (ESAOTE, Florence, Italy; 10-MHz linear array transducer, n=54), 157 
ESAOTE Picus Just 4D (ESAOTE, Maastricht, the Netherlands, 7.5-MHz linear array 158 
transducer, n=60), ESAOTE MyLabTM70 (ESAOTE, Maastricht, the Netherlands; 7.5-MHz 159 
linear array transducer, n=51), VIVID E9 (VIVID E9, General Electric, Waukesha, WI, USA, 160 
15-MHz linear array transducer, n=109), AU5 Armonic system (ESAOTE, Florence, Italy; 161 
7.0-MHz linear array transducer, n=136). One included study is a multi-centre study 162 
consisting of 7 sub-studies, which used a range of devices (ESAOTE, Philips, Siemens and 163 
General Electric, 7.5-10 MHz linear array transducer, n=110).  164 
 165 
All studies used (semi)automatic analysis software. However, different software was used 166 
across the centres:(1) Custom made MyFMD software, V2012.2, Prof. A.P.G. Hoeks, 167 
Department of Biomedical Engineering, Maastricht University, Maastricht, the Netherlands 168 
(n=130); (2) Custom made software [17], Pisa, Italy (n=135); (3) Custom made DICOM 169 
software for edge-detection (n=135) [18, 19]; and (4) FMD Studio, Cardiovascular Suite, 170 
ClinicalPhysiology, National ResearchCouncil, Pisa, Italy (n=272) [20, 21]. All centres 171 
collected continuous measurements of the diameter and recorded these (on either VCR or 172 
digitally) for post-study analyses. No study used fixed time points for diameter estimation. 173 
 174 
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Sources of variation 175 
Our primary outcome parameter was the variation between both FMD measurements, for 176 
which we calculated the coefficient of variation (CV) for each individual's repeated 177 
measurements, calculated as [(sdFMD/meanFMD)*100]. Furthermore, we recorded FMD 178 
(%), baseline diameter (cm), maximal diameter (cm), and time between measurements 179 
(categorized in <24h, 1-7 days, 8-14 days, 2-4 weeks, or >4 weeks).  180 
 181 
Measurement of subject-related factors. We included the following subject-related factors, 182 
that were all presented using a continuous scale; age (inclusion ≥18 years, range 18-82 years); 183 
weight (range 45-171 kg); height (range 1.55-1.94 m); body mass index (calculated as weight 184 
(kg)/ height2(m), range 17.6-55.8kg/m2); systolic- and diastolic blood pressure (in mmHg) and 185 
calculated mean arterial pressure [MAP, calculated as (2*diastolic pressure + systolic 186 
pressure) / 3, range 64-139 mmHg]; and blood-specific parameters (i.e. total cholesterol; high 187 
density lipoprotein, HDL; low density lipoprotein, LDL; triglycerides; glucose; all in 188 
mmol/L). All original parameters were rescaled to the same metric or most frequently used 189 
units (i.e. cholesterol and glucose values converted from mg/dL to mmol/L)[22]. 190 
 191 
We also presented subject-related factors using categorical scales: sex (male/female); 192 
presence of hypertension (conform current guidelines defined as: systolic pressure ≥140 193 
mmHg and/or diastolic pressure ≥90 mmHg, or using blood pressure-lowering drugs, yes/no); 194 
the presence of diabetes (type 1 or type 2); smoking status (yes/no/history of smoking); 195 
presence of dyslipidemia (yes/no, as specified by each contributing centre), and history and/or 196 
presence of cardiovascular disease (CVD).  197 
 198 
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Measurement of methodology-related parameters. All assessments followed the expert-199 
consensus FMD guidelines, ensuring that the protocol involved cuff placement around the 200 
forearm, occlusion for 5-minutes and cuff inflation ≥50 mmHg above systolic pressure. 201 
Furthermore, we assessed the following factors; use of a probe holder (yes/no); lab experience 202 
( total number of peer-reviewed publications that included measurement of FMD from 203 
contributing principal investigator through a Pubmed-based search using the search term 204 
“[author] AND flow mediated dilation”); mention of the laboratory’s own reported coefficient 205 
of variation (mentioned as CV% reported); use of continuous and/or ECG-gated diameter 206 
recording; measurement of artery diameter across the cardiac cycle; and the time between 207 
measurements (<24h, 1-7 days, 8-14 days, 2-4 weeks, and >4 weeks). The Supplementary 208 
material provides details of the questionnaire used to assess these factors. 209 
 210 
Missing values 211 
Since missing data were present for all of the 82 individual parameters, we used multiple 212 
imputation chained equations to impute parameters. We performed this procedure with a 213 
maximum up to 30%, as previously described [23, 24]. Parameters for which 31% or more 214 
was data were missing, were excluded from analyses and are not further mentioned. A more 215 
detailed outline of the imputation model can be found in the Supplementary material.  216 
 217 
Statistical analysis 218 
All data are presented as N(%) or mean ± standard deviation unless stated otherwise. The 219 
main outcome measure for the reproducibility of the FMD is the coefficient of variation (CV) 220 
calculated for the mean difference between both FMD measurements. All descriptive data 221 
were examined in the pooled dataset and in quartiles of variation in FMD (i.e. CV). Based on 222 
the CV, we qualified the reproducibility as excellent (0-10%), good (10-20%), moderate (20-223 
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30%) or poor (>30%)[25]. In multiple linear regression analyses we used the (log 224 
transformed) FMD CV as the dependent variable to identify factors that independently 225 
contributed to the variability of the FMD measurement, using backward regression analysis. 226 
A total of 4 models were constructed; Model 1a - Subject-related factors (continuous scale), 227 
Model 1b–Subject-related factors (categorical scale, i.e. presence of hypertension), Model 2–228 
Methodology-related factors, and Model 3–Significant factors from previous models 1a-1b-2. 229 
Details of all regression models are given in the Supplemental information. All statistical 230 
analyses were performed using the Statistical Package for Social Sciences, version 20.0 231 
(SPSS, INC. Chicago, IL, USA). 232 
 233 
 234 
RESULTS 235 
A median CV of 17.5% was observed for the entire population of 672 subjects, whilst a 236 
median CV of 9.3% was observed for volunteers without CV risk factors (n=109). We 237 
observed substantial variation between subjects regarding the individual CV for the FMD% 238 
(Figure 1). When dividing subjects into 4 quartiles, we calculated the CV for each quartile 239 
(Mean CV 29.9±46.5, range 0.14-745.33; Median CV Quartile-1 3.25%; Quartile-2 11.74%; 240 
Quartile-3 24.76%; Quartile-4 61.03%). We found an excellent, good or moderate CV in 33% 241 
(n=221), 22% (n=147), and 14% (n=94) of the sample, respectively. A poor CV was observed 242 
in 31% of the cases (n=210). 243 
 244 
Subject-related factors 245 
Age, BMI, total cholesterol, and glucose levels showed a gradual increase across quartiles, 246 
with Q3 and Q4 (i.e. large variation in FMD) showing significantly higher values than Q1 247 
(Table 1). Systolic, diastolic and mean blood pressure were highest in Q2-3, whilst this 248 
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difference was lost in Q4 (Table 1). When subject-related factors were presented using a 249 
categorical scale, hypertension and dyslipidemia had significant impact on the reproducibility 250 
of the FMD (presence of hypertension Q1 15.5%, Q2 30.4%, Q3 32.1% and Q4 21.4%, 251 
diabetes Q1 0%, Q2 0%, Q3 1.2% and Q4 0.6%, both P<0.001), but not sex, smoking status, 252 
diabetes mellitus and CVD. 253 
 254 
Methodology-related factors 255 
FMD% and baseline diameter were significantly different across quartiles of the CV (Table 256 
2). Subject in Q4 had a lower FMD and a larger baseline diameter (Table 2). We found that 257 
all factors related to the practical performance of the FMD, except the use of a probe holder, 258 
were significantly different between quartiles (Table 2). Larger variation in CV FMD% (i.e. 259 
Q3-4) was associated with absence of ECG-gated recording, no measurement of the diameter 260 
across the cardiac cycle, longer time between tests, less experience of the research centre in 261 
FMD measurements, and absence of reporting the CV of the laboratory in manuscripts (Table 262 
2). 263 
 264 
Regression analyses 265 
Model 1a – Subject-related factors (continuous). After including all subject-related factors 266 
that significantly differed across quartiles, this model showed an R2=0.087 and adjusted 267 
R2=0.086. We found that only age predicted variation in FMD%CV (β=0.248, ratio of 28.1%, 268 
CI[0.020-0.035], p-value <0.001).  269 
 270 
Model 1b–Subject-related factors (categorical). Including all subject-related factors that 271 
differed across quartiles, we found an R2=0.112 and adjusted R2=0.108. We identified 272 
hypertension (β=0.104, ratio of 11%, CI[0.095-0.533], p-value 0.005), dyslipidemia (β=0.331, 273 
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ratio of 39.2%, CI [0.813-1.275], p-value <0.001) and sex (β=-0.069, ratio of -6.7%, CI [-274 
0.390-0.010], p-value 0.063) as significant predictors for the reproducibility of the FMD%. 275 
 276 
Model 2–Methodology-related factors. This model showed an R2=0.198 and adjusted 277 
R2=0.184 when including methodology-related factors that differed across quartiles. The 278 
model identified time between measurements (β=0.318, ratio of 37.5%,CI[0.179-0.298], p-279 
value <0.001), FMD% at baseline (β=-0.124, ratio of -11.7%, CI [-0.098--0.021], p-value 280 
0.002), baseline diameter (β=0.082, ratio of 8.6%, CI[0.007-0.270], p-value 0.039) and lab 281 
experience (β=-0.133, ratio of -12.4%, CI [-0.011--0.003], p-value 0.001) as significant 282 
contributors to the variation in FMD% CV.  283 
 284 
Model 3 - Overall model 285 
Factors identified by models 1a, 1b and 2 were included in the overall model which resulted 286 
in an R2=0.208 and adjusted R2=0.202. Backward linear regression analysis identified time 287 
between measurements (β=0.291, ratio of 33.8%, CI [0.156-0.273], p-value <0.001), 288 
hypertension (β=0.096, ratio of 10.1%, CI[0.068-0.501], p-value 0.010), baseline FMD% (β=-289 
0.142, ratio of -13.3%, CI [-0.105--0.030], p-value <0.001) and lab experience (β=-0.131, 290 
ratio of -12.3%, CI [-0.012--0.003], p-value 0.001) as significant contributors to the variation 291 
in FMD% across 2 repeated measurements (Figure 2). Baseline diameter demonstrated a 292 
borderline significant association with FMD% reproducibility (β=0.070, ratio of 7.2%, CI [-293 
0.015-0.242], p-value 0.084). 294 
 295 
 296 
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DISCUSSION 297 
This study included 672 repeated measurement of the brachial artery FMD, involving data 298 
from different research centres and various populations. This allowed us to comprehensively 299 
explore factors contributing to the within-subject variability of brachial artery FMD%, when 300 
measured according contemporary guidelines [11]. We present the following observations. 301 
First, the majority of the measurements showed an excellent-to-good reproducibility. For 302 
asymptomatic subjects, the median CV was 9.3%. This demonstrates that FMD is a 303 
reproducible tool to assess endothelial function in vivo. Secondly, we also found substantial 304 
variation between individuals in the CV of FMD%. In particular, the presence of hypertension 305 
contributed to a larger variation in FMD%, independent of other factors. Third, we found that 306 
a poorer reproducibility of the FMD was associated with the presence of a lower baseline 307 
FMD%, a higher baseline brachial artery diameter, a longer time period between repeated 308 
measurements, and less experience of the laboratory with the FMD measurement. Taking 309 
these factors into consideration for sample size calculations in future studies will help to 310 
decrease chances of type II errors. 311 
 312 
Subject-related factors 313 
Several previous studies have explored and described reproducibility of brachial artery FMD 314 
and presented mixed results, ranging from an excellent to poor reproducibility [13, 26, 27]. 315 
The overall median CV% in our analysis of 17.5% in the whole study population, and 9.3% in 316 
subjects without CV risk/disease, are in line with findings of most previous studies that 317 
reported a good reproducibility [14, 16, 28-30]. An important strength of our analysis is the 318 
large number of repeated measurements, which allowed us to identify between-subject and –319 
laboratory related factors contributing to the variation in brachial artery FMD% within an 320 
individual. Interestingly, we found that older age, dyslipidemia and presence of hypertension 321 
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were related to larger variation in FMD%. This suggests, in agreement with previous work 322 
[28], that reproducibility of the FMD may be lower in populations with clinical symptoms 323 
than in healthy, young subjects.  324 
 325 
An explanation for the larger variation in clinical populations could be the presence of a lower 326 
baseline FMD% that is typically observed in older subjects [31] and in those with 327 
hypertension [32], CVD [33] or dyslipidemia [14]. Indeed, we found that baseline FMD% is a 328 
strong and independent predictor for larger variability. Therefore, baseline FMD% was added 329 
to the statistical model to explore its impact on variability in FMD% independent of older age, 330 
hypertension and dyslipidemia. Interestingly, in this model the impact of age and 331 
dyslipidemia disappeared, suggesting that the lower baseline FMD% in older subjects is at 332 
least partly responsible for the larger variation with increasing age. In contrast, the impact of 333 
hypertension remained significant, indicating that other factors play a role in the larger 334 
variation in repeated measurements of brachial artery FMD%. Possibly, this poorer 335 
reproducibility may relate to higher stiffness of the vessels in clinical populations, compared 336 
to healthy volunteers [34]. Craiem et al. also found that subjects with CVD, despite 337 
comparable baseline FMD% values, demonstrate a larger coefficient of variation compared to 338 
healthy controls [28]. 339 
 340 
Methodology-related factors 341 
Identification of methodology-related factors that contribute to the variation in FMD is highly 342 
relevant because such factors can potentially be controlled for. Several previous studies have 343 
highlighted the importance of methodological factors, which formed the basis for the FMD 344 
expert consensus guidelines [11]. The present study identified time between measurements 345 
and lab experience as independent determinants of the variation in FMD%, with more time 346 
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between FMD measurement leading to a higher CV. Most studies that explored FMD 347 
reproducibility included fixed time points between measurements, which makes direct 348 
comparisons of the duration between testing difficult. Interestingly, Charakida et al. explored 349 
FMD reproducibility after a few hours, 2 day, 3 months and 9 month [35]. In agreement with 350 
our findings, this study also demonstrate a poorer CV with increased time between re-testing. 351 
In contrast, Sorensen et al. found no difference in reproducibility when FMD was repeated 352 
after 1-2 days, 1-2 weeks or 2-4 months [27]. However, this study did not apply FMD 353 
measurements according to current guidelines, which may have affected the results. Whilst 354 
longer time between repeated measures may be associated with increased variability due to 355 
purely methodological variation, it is also likely that true biological variability is greater 356 
under circumstances where the repeated measure is more distant in time.  357 
 358 
Laboratories that provided data for this analysis adopted expert consensus guidelines to 359 
perform and analyse FMD. This makes it difficult to explore the importance, for 360 
reproducibility, of the individual aspects within these guidelines. Nonetheless, our analysis 361 
showed that laboratory experience with FMD measurements independently contributes to the 362 
variation in FMD measurement. More specifically, the greater the experience of a laboratory 363 
with the FMD technique, the smaller the variation between repeated FMD measurements. 364 
This somewhat self-evident finding is nonetheless important, as it should guide laboratories 365 
who adopt the technique in attaining the level of practice and experience required before 366 
robust measures can be assumed. Nonetheless, limited experience of FMD did not completely 367 
invalidate assessment: the subgroup of healthy subjects without CV risk/disease that showed a 368 
CV of 9.3±19% (n=109) included data from both experienced and less experienced 369 
laboratories, demonstrating the feasibility of a low CV in FMD measurements. This is in 370 
accordance with previous multi-centre studies [16]. These data demonstrate the importance of 371 
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adherence to the expert-consensus guidelines in addition to a priori practice and experience 372 
with the FMD-technique. 373 
 374 
Practical relevance. This study demonstrates that, in addition to adopting current guidelines, 375 
some factors should be considered that might affect the variation of the FMD. For example, 376 
larger FMD reproducibility is observed when the time between measurements increases 377 
and/or in the presence of hypertension, and low resting FMD%. These factors should be taken 378 
into consideration when performing a sample size calculation and in the design of the study. 379 
Furthermore, the data of this study also emphasise that, in addition to fair reproducibility of 380 
the FMD in less experienced laboratories, training and gaining more experience is likely to 381 
minimise measurement error of the FMD-technique. 382 
 383 
Limitations. One limitation of our study is that it was not prospectively designed to address 384 
FMD reproducibility. This may have introduced some error, especially relating to controlling 385 
physical activity and/or dietary instructions for the time between testing. However, all data 386 
was collected as in a ‘real world’ study rather than being set-up as a reproducibility study. 387 
Therefore, our study possesses ecological validity and can be extrapolated to various research 388 
settings. Another limitation is that all data in our analysis derive from laboratories adopting 389 
current guidelines for FMD measurement. Therefore, we were unable to address the relative 390 
importance of individual aspects included in these guidelines. In addition, whilst all centres 391 
indicated they adhered to the expert-consensus guidelines, we have no specific data on the internal 392 
control of adherence and/or small variation within these guidelines between centres (e.g. differences in 393 
analysis software, ultrasound machines). Such differences may in part contribute to the inherent 394 
variability of the FMD. 395 
 396 
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In conclusion, we have shown in a large dataset of repeated measurements that the majority of 397 
FMD measurements show an excellent-to-moderate reproducibility. Despite adopting expert 398 
consensus guidelines, several subject and methodology-related factors have independent 399 
impact on the variation in FMD% between two measurements. These include the presence of 400 
hypertension, a lower resting FMD%, a larger baseline artery diameter, a longer time between 401 
subsequent measurements, and less laboratory experience with the measurement. Future 402 
studies should take these subject- and methodology-related factors into consideration to 403 
improve sample size calculation. Such procedures will importantly decrease variability of the 404 
FMD and, consequently, decrease chances for type II errors in studies that rely on FMD as 405 
their primary outcome parameter.  406 
 407 
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FIGURE LEGENDS 517 
Figure 1. Individual reproducibility in Brachial artery FMD 518 
Data of all subjects (n=672) relating to the individual reproducibility of the brachial artery 519 
FMD across 2 repeated measurements. 520 
 521 
Figure 2. Regression analysis  522 
Plot for regression coefficient β for the coefficient of variation (CV) of the flow mediated 523 
dilation (FMD). * implies a statistical significant contribution in final model. 524 
 525 
 526 
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TABLES 527 
Table 1. Subject-related factors 528 
Continuous scale Pooled {29.9±46.5} 
Quartile 1 
{3.25%} 
Quartile 2 
{11.74%} 
Quartile 3 
{24.76%} 
Quartile 4 
{61.03%} P-value 
Age (years) 46±17 (655) 40±16 163 
42±15 
164 
46±16* 
164 
54±16* 
164 <0.001 
Sex (% male) 66 671 
64 
168 
67 
168 
68 
167 
67 
168 0.895 
Weight (kg) 77.4±13.1 636 
75.9±12.1 
163 
76.7±11.8 
161 
78.6±14.4 
160 
78.3±14.1 
152 0.210 
Height (cm) 1.75±0.1 637 
1.76±0.1 
163 
1.76±0.1 
161 
1.75±0.1 
160 
1.75±0.1 
152 0.657 
BMI (kg/m) 25.3±3.7 657 
24.6±3.4 
164 
24.9±3.3 
165 
25.8±4.2* 
164 
25.9±3.5* 
164 0.003 
Systolic BP 
(mmHg) 
129±15 
645 
127±13 
161 
131±14* 
163 
130±16* 
159 
128±15 
162 0.023 
Diastolic BP 
(mmHg) 
79±11 
645 
78±11 
161 
81±12* 
163 
79±12 
159 
76±11 
162 <0.001 
Mean BP (mmHg) 96±12 655 
94±11 
135 
98±12* 
165 
96±13 
163 
94±11 
164 0.002 
Cholesterol 
(mmol/L) 
5.3±1.0 
544 
5.1±1.0 
135 
5.2±1.0 
134 
5.4±1.0* 
134 
5.6±0.9* 
141 <0.001 
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HDL (mmol/L) 1.4±0.4 508 
1.4±0.3 
127 
1.4 ±0.3 
126 
1.4±0.3 
124 
1.4±0.4 
131 0.414 
LDL (mmol/L) 3.5±0.8 466 
3.3±0.8 
115 
3.3±0.8 
109 
3.5±0.9* 
112 
3.7±0.8* 
130 <0.001 
Triglycerides 
(mmol/L) 
1.4±1 
529 
1.3±0.8 
129 
1.4±1.3 
130 
1.4±0.9 
130 
1.3±0.8 
140 0.924 
Glucose (mmol/L) 5.1±0.7 466 
5.0±0.7 
132 
5.0±0.9 
132 
5.0±0.7 
114 
5.4±0.7* 
88 <0.001 
         Subject-related factors for whole group (n=672) and quartiles (of n=168 each) with median CV reported per quartile. Data are reported as mean 529 
± SD with total number of subjects available for analysis presented below in italic. P-value refers to an ANOVA. *Post-hoc significantly different 530 
from Quartile 1 at P<0.05  531 
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Table 2. Methodological-related factors 532 
Continuous scale Pooled {29.9±46.5} 
Quartile 1 
{3.25%} 
Quartile 2 
{11.74%} 
Quartile 3 
{24.76%} 
Quartile 4 
{61.03%} P-value 
Baseline diameter 
(mm) 
4.3±0.8 
672 
4.1±0.8 
168 
4.3±0.7* 
168 
4.4±0.8* 
168 
4.4±0.8* 
168 <0.001 
Maximal diameter 
(mm) 
4.5±0.8 
672 
4.3±0.8 
168 
4.5±0.7* 
168 
4.6±0.9* 
168 
4.5±0.8* 
168 <0.001 
FMD (%) 5.4±3.0 672 
6.1±2.8 
168 
5.8±2.4 
168 
5.7±2.8 
168 
4.1±3.6* 
168 <0.001 
Laboratory experience 
(papers per PI) 
29.2±24.8 
672 
35.6±21.9 
168 
35.1±22.9 
168 
30.9±25.3* 
168 
15.4±23.6* 
168 <0.001 
CV reported (%) 16.8±9.5 612 
14.7±6.9 
155 
14.6±6.7 
160 
16.5±9.5 
158 
22.2±12.4 
139 <0.001 
Categorial scale       
Analysis by laboratory 96 672 
99 
168 
99 
168 
95* 
168 
92* 
168 <0.001 
ECG-gated recording 28 672 
25 
168 
38* 
168 
35* 
168 
13* 
168 <0.001 
Cardiac cycle (%) 84 672 
87 
168 
88 
168 
87 
168 
73* 
168 <0.001 
Probe holder (%) 80 672 
77 
168 
79 
168 
77 
168 
86 
168 0.110 
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Time:  <24 hours (%) 53 69 69 52 21 <0.001 
 1-7 days (%) 
 8-14 days (%) 
6 
7 
6 
5 
9 
5 
6 
10 
4 
8  
 2-4 weeks (%) 
 >4weeks (%) 
9 
25 
9 
11 
6 
11 
8 
24 
11 
56  
 672 168 168 168 168  
 533 
 Methodological-related factors presented for whole group (n=672) and quartiles (n=168 each) with median CV reported per quartile. Data are 534 
reported as mean ± SD with the total number of subjects available for analysis presented below in italic. P-value refers to an ANOVA. *Post-hoc 535 
significantly different from Quartile 1 at P<0.05. 536 
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